search
Back to results

Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C (TEA)

Primary Purpose

IBS, Constipation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Transcutaneous Electrical Acustimulation (TEA)
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IBS

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Willing to comply with all study procedures and be available for the duration of the study
  • Diagnosed with IBS-C satisfying Rome IV criteria
  • Have symptoms present for at least the last 3 months
  • Have abdominal pain that is not adequately relieved at the time of screening and the time of randomization
  • Has a VAS pain score of >3 (on 0-10 score)

Exclusion Criteria:

  • Have an unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes, unstable thyroid disease
  • Have history of abdominal surgery (other than cholecystectomy or appendectomy)
  • Are taking anticoagulants or antispasmodic, antidiarrheal, or opioids or other pain relief medications and cannot stop these medications for three consecutive days before each study visit
  • Are pregnant or lactating; women of child bearing potential complete a pregnancy test at each visit
  • Have known allergic reactions to components of the ECG electrodes
  • Received treatment with an investigational drug or other intervention within 6 months of the date of consent
  • Anything that, in the opinion of the investigator, would place the study participant at increased risk or preclude the study participant's full compliance with or completion of the study
  • Are unable to provide informed consent

Sites / Locations

  • University of Michigan

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Subjects with IBS-C

Arm Description

All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.

Outcomes

Primary Outcome Measures

Change in pressure of maximum tolerance in mmHg of the rectum as measured by a barostat device when compared to pre-TEA administration.
The barostat device will measure the pressure changes in the rectum during controlled distension of the gastrointestinal organs. The study participant's maximum tolerance of distention will be compared to tolerance pre and post TEA, as well as comparing each administration to the other modalities and the sham.
Change in pressure of maximum tolerance in mmHg of the rectum as measured by a barostat device when compared to other modalities (body position, frequency and sham)
The barostat device will measure the pressure changes in the rectum during controlled distension of the gastrointestinal organs. The study participant's maximum tolerance of distention will be compared to tolerance pre and post TEA, as well as comparing each administration to the other modalities and the sham.

Secondary Outcome Measures

Change in pain as measured by Visual Analog Scale (VAS) surveys when compared to pre-TEA administration.
VAS surveys, a pain scale from 1(lowest) to 10 (highest), will be taken to assess efficacy of treatment on a 10 point scale.
Change in pain as measured by Visual Analog Scale (VAS) surveys when compared to other modalities (body position, frequency and sham)
VAS surveys, a pain scale from 1(lowest) to 10 (highest), will be taken to assess efficacy of treatment on a 10 point scale.

Full Information

First Posted
June 28, 2021
Last Updated
March 29, 2023
Sponsor
University of Michigan
Collaborators
National Institutes of Health (NIH), Transtimulation Research, Inc, National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT04953728
Brief Title
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
Acronym
TEA
Official Title
TEA for Study Participants With IBS-C Optimization of TEA Modalities for Treatment of IBS-C: A Phase 1 25 Study Participant Clinical Trial of Transcutaneous Electrical Acustimulation (TEA) in Study Participants With IBS-C
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
December 5, 2022 (Actual)
Study Completion Date
December 5, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan
Collaborators
National Institutes of Health (NIH), Transtimulation Research, Inc, National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to determine the most effective treatment with Transcutaneous Electrical Acustimulation (TEA) for Irritable Bowel Syndrome with Constipation (IBS-C) by comparing efficacy between 5 separate sessions. The rectum pressure as measured by a device called a barostat will be compared between visits. Each session will be testing a different combination of frequency and body position of the electrodes. Electrodes placed at either the wrist or knee will be stimulated at either 25 Hz or 100 Hz.
Detailed Description
This study aims to discern whether Transcutaneous Electrical Acustimulation (TEA) at acupuncture points ST36 and/or PC6 will relieve the abdominal pain associated with IBS-C. Each study participant will have 5 research visits at the Michigan Medicine GI physiology lab. During these visits, they will undergo a procedure similar to Anal Rectal Manometry (ARM) performed by the GI physiology lab staff. TEA is similar to this procedure as it is uses the barostat device and is performed by the GI physiology lab staff. This device has a rubber catheter that will be inserted 5-15 cm into the rectum of the study participant. Then the GI physiology staff will inflate the catheter. They will ask the study participant when they can sense the catheter. Then the GI physiology staff will continue to inflate the catheter and the study participants feel discomfort (described as the 'urge to defecate'). Then the study participant will be asked to pass the balloon (like they would pass a bowel movement). The difference between ARM procedure and the study procedure is that there will be stimulation of acupuncture point ST36 which is below the knee cap or stimulation of acupuncture point PC6 which is just above the wrist. For this study, this mild electrical stimulation will occur simultaneously with the barostat procedure. At each visit there will be stimulation of only one of the points at either 100Hz or 25Hz. These are the potential combinations: ST36 100Hz, ST36-25Hz, PC6-100Hz, PC6-25Hz, Sham-TEA. The frequency and position combination (or sham visit) is randomly assigned. The randomization determines the order in which the study participant moves through the study. Every study participant will, in the end, complete one visit at each frequency and a sham visit. The study participant will also complete surveys at the appointment. The TEA device is classified by the FDA as a non-significant risk device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IBS, Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
All participants will receive all treatments including sham comparator in a randomized order. Subjects will not be informed of which treatment they will be receiving or the treatment order to which they are assigned.
Allocation
N/A
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects with IBS-C
Arm Type
Experimental
Arm Description
All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
Intervention Type
Device
Intervention Name(s)
Transcutaneous Electrical Acustimulation (TEA)
Intervention Description
Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
Primary Outcome Measure Information:
Title
Change in pressure of maximum tolerance in mmHg of the rectum as measured by a barostat device when compared to pre-TEA administration.
Description
The barostat device will measure the pressure changes in the rectum during controlled distension of the gastrointestinal organs. The study participant's maximum tolerance of distention will be compared to tolerance pre and post TEA, as well as comparing each administration to the other modalities and the sham.
Time Frame
Pressure will be measured 6 times approximately 5 minutes apart during each visit. 5 visits will occur between 1 and 3 weeks apart.
Title
Change in pressure of maximum tolerance in mmHg of the rectum as measured by a barostat device when compared to other modalities (body position, frequency and sham)
Description
The barostat device will measure the pressure changes in the rectum during controlled distension of the gastrointestinal organs. The study participant's maximum tolerance of distention will be compared to tolerance pre and post TEA, as well as comparing each administration to the other modalities and the sham.
Time Frame
Pressure will be measured 6 times approximately 5 minutes apart during each visit. 5 visits will occur between 1 and 3 weeks apart.
Secondary Outcome Measure Information:
Title
Change in pain as measured by Visual Analog Scale (VAS) surveys when compared to pre-TEA administration.
Description
VAS surveys, a pain scale from 1(lowest) to 10 (highest), will be taken to assess efficacy of treatment on a 10 point scale.
Time Frame
VAS surveys will be taken 6 times approximately 5 minutes apart during each visit. 5 visits will occur between 1 and 3 weeks apart.
Title
Change in pain as measured by Visual Analog Scale (VAS) surveys when compared to other modalities (body position, frequency and sham)
Description
VAS surveys, a pain scale from 1(lowest) to 10 (highest), will be taken to assess efficacy of treatment on a 10 point scale.
Time Frame
VAS surveys will be taken 6 times approximately 5 minutes apart during each visit. 5 visits will occur between 1 and 3 weeks apart.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing to comply with all study procedures and be available for the duration of the study Diagnosed with IBS-C satisfying Rome IV criteria Have symptoms present for at least the last 3 months Have abdominal pain that is not adequately relieved at the time of screening and the time of randomization Has a VAS pain score of >3 (on 0-10 score) Exclusion Criteria: Have an unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes, unstable thyroid disease Have history of abdominal surgery (other than cholecystectomy or appendectomy) Are taking anticoagulants or antispasmodic, antidiarrheal, or opioids or other pain relief medications and cannot stop these medications for three consecutive days before each study visit Are pregnant or lactating; women of child bearing potential complete a pregnancy test at each visit Have known allergic reactions to components of the ECG electrodes Received treatment with an investigational drug or other intervention within 6 months of the date of consent Anything that, in the opinion of the investigator, would place the study participant at increased risk or preclude the study participant's full compliance with or completion of the study Are unable to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiande Chen, Ph.D.
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
De-identified individual participant data will not be shared. However, the study protocol and the study results will be shared
Citations:
PubMed Identifier
25989154
Citation
Ma D, Han JS, Diao QH, Deng GF, Ping XJ, Jin WJ, Wu LZ, Cui CL, Li XD. Transcutaneous electrical acupoint stimulation for the treatment of withdrawal syndrome in heroin addicts. Pain Med. 2015 May;16(5):839-48. doi: 10.1111/pme.12738. Erratum In: Pain Med. 2015 Nov;16(11):2217.
Results Reference
background
PubMed Identifier
24657460
Citation
Jiang Y, Liu J, Liu J, Han J, Wang X, Cui C. Cerebral blood flow-based evidence for mechanisms of low- versus high-frequency transcutaneous electric acupoint stimulation analgesia: a perfusion fMRI study in humans. Neuroscience. 2014 May 30;268:180-93. doi: 10.1016/j.neuroscience.2014.03.019. Epub 2014 Mar 20.
Results Reference
background
PubMed Identifier
28915981
Citation
Qu F, Wang FF, Wu Y, Zhou J, Robinson N, Hardiman PJ, Pan JX, He YJ, Zhu YH, Wang HZ, Ye XQ, He KL, Cui L, Zhao HL, Ye YH. Transcutaneous Electrical Acupoint Stimulation Improves the Outcomes of In Vitro Fertilization: A Prospective, Randomized and Controlled Study. Explore (NY). 2017 Sep-Oct;13(5):306-312. doi: 10.1016/j.explore.2017.06.004. Epub 2017 Jun 30.
Results Reference
background
PubMed Identifier
31347247
Citation
Yu Y, Wei R, Liu Z, Xu J, Xu C, Chen JDZ. Ameliorating Effects of Transcutaneous Electrical Acustimulation Combined With Deep Breathing Training on Refractory Gastroesophageal Reflux Disease Mediated via the Autonomic Pathway. Neuromodulation. 2019 Aug;22(6):751-757. doi: 10.1111/ner.13021. Epub 2019 Jul 26.
Results Reference
background
PubMed Identifier
29925916
Citation
Zhang B, Xu F, Hu P, Zhang M, Tong K, Ma G, Xu Y, Zhu L, Chen JDZ. Needleless Transcutaneous Electrical Acustimulation: A Pilot Study Evaluating Improvement in Post-Operative Recovery. Am J Gastroenterol. 2018 Jul;113(7):1026-1035. doi: 10.1038/s41395-018-0156-y. Epub 2018 Jun 21.
Results Reference
background

Learn more about this trial

Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C

We'll reach out to this number within 24 hrs